SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-007013
Filing Date
2021-05-13
Accepted
2021-05-13 09:45:15
Documents
85
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q casi-20210331x10q.htm   iXBRL 10-Q 1401955
2 EX-10.1 casi-20210331xex10d1.htm EX-10.1 563730
3 EX-31.1 casi-20210331xex31d1.htm EX-31.1 12950
4 EX-31.2 casi-20210331xex31d2.htm EX-31.2 12784
5 EX-32.1 casi-20210331xex32d1.htm EX-32.1 7205
6 EX-32.2 casi-20210331xex32d2.htm EX-32.2 7260
  Complete submission text file 0001558370-21-007013.txt   7375071

Data Files

Seq Description Document Type Size
7 EX-101.SCH casi-20210331.xsd EX-101.SCH 65395
8 EX-101.CAL casi-20210331_cal.xml EX-101.CAL 49457
9 EX-101.DEF casi-20210331_def.xml EX-101.DEF 192206
10 EX-101.LAB casi-20210331_lab.xml EX-101.LAB 455719
11 EX-101.PRE casi-20210331_pre.xml EX-101.PRE 391858
12 EXTRACTED XBRL INSTANCE DOCUMENT casi-20210331x10q_htm.xml XML 1101073
Mailing Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850
Business Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850 240-864-2600
CASI Pharmaceuticals, Inc. (Filer) CIK: 0000895051 (see all company filings)

IRS No.: 581959440 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-20713 | Film No.: 21917619
SIC: 2836 Biological Products, (No Diagnostic Substances)